Actionable news
0
All posts from Actionable news
Actionable news in NLNK: NewLink Genetics Corporation,

NewLink Pancreatic Cancer Vaccine Fails, May Even Harm Patients

An experimental cancer vaccine developed by NewLink Genetics (NLNK - Get Report) failed to prolong survival in patients with pancreatic cancer compared to a standard therapy, according to results from a phase III study disclosed Monday.

NewLink shares were halted at $16.50 ahead of the trial results being announced. When trading re-opened, NewLink shares fell 36% to $10.60.

The NewLink vaccine, known as algenpantucel-L, was designed to stimulate a patient's immune system to recognize and kill cancer cells. It did no such thing.

Pancreatic cancer patients...


More